

Figure S3: Development of high SARS-CoV-2 IgG avidities in three SARS-CoV-2 patients.




Figure S3: continued.

SARS-CoV-2

Patient 18

				Reaktivität	IgG(1)	IgA(2)	IgM(3)	CutOff(4)	NP_229E(5)	NP_NL63(6)	NP_OC43(7)	NP_HKU1(8)	NP_SARS_2(9)	RBD_SARS_2(10)	S1_SARS_2(11)		
				LCO 01	0	1	4		9	10	11						
26 d.a.P.	1	Avidität	IgG	42136433	LCO 02	0	1	2	4	9	10	11			NP_SARS_2(0.39=n);RBD_SARS_2(0.29=n);S1_SARS_2(0.33=n)		
	2	Patient	IgG	42136433	LCO 04	0	1	2	4	9	10	11			NP_SARS_2(6,4); RBD_SARS_2(4,9); S1_SARS_2(6,1)		
46 d.a.P.	3	Avidität	IgG	42158360	LCO 05	0	1	2	4	9	10	11			NP_SARS_2(0.16=n);RBD_SARS_2(0.20=n);S1_SARS_2(0.43=n)		
	4	Patient	IgG	42158360	LCO 06	0	1	2	4	8	9	10	11			NP_SARS_2(3,0); RBD_SARS_2(4,6); S1_SARS_2(5,7)	
91 d.a.P.	5	Avidität	IgG	42221386	LCO 08	0	1	4	5	6	9	10	11			NP_229E(0.70=h);NP_NL63(0.82=h);NP_SARS_2(0.17=n);RBD_SARS_2(0.17=n);S1_SARS_2(0.24=n)	
	6	Patient	IgG	42221386	LCO 08	0	1	4	5	6	9	10	11			NP_229E(1,3); NP_NL63(1,8); NP_SARS_2(5,1); RBD_SARS_2(2,8); S1_SARS_2(3,3)	
130 d.a.P.	9	Avidität	IgG	42271849	LCO 10	0	1	4		9	10	11				NP_SARS_2(0.35=n);RBD_SARS_2(0.83=h);S1_SARS_2(0.79=h)	
	10	Patient	IgG	42271849	LCO 10	0	1	4		9	10	11				NP_SARS_2(4,5); RBD_SARS_2(4,4); S1_SARS_2(5,1)	
147 d.a.P.	3	Patient	IgG	42299533	LCO 07	0	1	2	4	7	8	9	10	11			NP_SARS_2(6,6); RBD_SARS_2(6,4); S1_SARS_2(6,7)
	4	Avidität	IgG	42299533	LCO 01	0	1	2	4	8	9	10	11			NP_SARS_2(0.29=n);RBD_SARS_2(0.68=h);S1_SARS_2(0.71=h)	

SARS-CoV-2

Patient 21

				Reaktivität	IgG(1)	IgA(2)	IgM(3)	CutOff(4)	NP_229E(5)	NP_NL63(6)	NP_OC43(7)	NP_HKU1(8)	NP_SARS_2(9)	RBD_SARS_2(10)	S1_SARS_2(11)		
				LCO 05	0	1	4	5	6	7	8	9	10	11			
19 d.a.P.	5	Patient	IgG	42141894	LCO 06	0	1	4	5	6	7	8	9	10	11	NP_OC43(1,1); NP_HKU1(1,7); NP_SARS_2(5,7); RBD_SARS_2(3,5); S1_SARS_2(3,9)	
	6	Avidität	IgG	42141894	LCO 06	0	1	4	5	7	8	9	10	11		NP_OC43(0.25=n);NP_HKU1(0.52=n);NP_SARS_2(0.34=n);RBD_SARS_2(0.20=n);S1_SARS_2(0.16=n)	
65 d.a.P.	23	Patient	IgG	42199832	LCO 12	0	1	4	5	6	7	8	9	10	11	NP_229E(1,2); NP_NL63(1,7); NP_OC43(1,9); NP_HKU1(2,1); NP_SARS_2(8,0); RBD_SARS_2(6,2); S1_SARS_2(6,7)	
	24	Avidität	IgG	42199832	LCO 12	0	1	4	5	6	7	8	9	10	11	NP_229E(0.67=h);NP_NL63(0.40=n);NP_OC43(0.25=n);NP_HKU1(0.69=h);NP_SARS_2(0.88=h);RBD_SARS_2(0.61=h);S1_SARS_2(0.55=n)	
104 d.a.P.	1	Avidität	IgG	42254953	LCO 09	0	1	4		8	9	10	11			NP_HKU1(0.26=n);NP_SARS_2(0.66=h);RBD_SARS_2(0.41=n);S1_SARS_2(0.46=n)	
	2	Patient	IgG	42254953	LCO 10	0	1	4	5	6	7	8	9	10	11		NP_HKU1(1,6); NP_SARS_2(7,5); RBD_SARS_2(5,4); S1_SARS_2(5,4)
121 d.a.P.	3	Patient	IgG	42277754	LCO 20	0	1	4	5	6	7	8	9	10	11		NP_229E(1,0); NP_NL63(1,5); NP_OC43(1,9); NP_HKU1(2,0); NP_SARS_2(7,6); RBD_SARS_2(6,2); S1_SARS_2(6,3)
	4	Avidität	IgG	42277754	LCO 20	0	1	4	5	6	7	8	9	10	11		NP_229E(0.53=n);NP_NL63(0.32=n);NP_OC43(0.20=n);NP_HKU1(0.50=n);NP_SARS_2(0.88=h);RBD_SARS_2(0.52=n);S1_SARS_2(0.52=n)

d.a.P., days after the positive SARS-CoV-2 PCR